From today, patients in England and Wales living with advanced renal cell carcinoma, a type of kidney cancer, can access Votrient� (pazopanib) on the National Health Service (NHS).1 The National Institute for Health and Clinical Excellence (NICE) has issued positive final guidance (known as Technology Appraisal Guidance - (TAG) for Votrient, a targeted oral treatment, which has been shown to effectively slow down disease progression whilst maintaining quality of life compared with placebo...
No comments:
Post a Comment